Early research at Mayo Clinic using stem cell therapy to treat spinal cord injuries has produced results for one patient that doctors describe as “beyond expectations.”
ROCHESTER, Minn. — Stem cells derived from a patient’s own fat offer a step toward improving — not just stabilizing — motor and sensory function of people with spinal cord injuries, according to early research from Mayo Clinic.
A clinical trial enrolled 10 adults to treat paralysis from traumatic spinal cord injury. After stem cell injection, the first patient demonstrated improvement in motor and sensory functions, and had no significant adverse effects, according to a case report published in Mayo Clinic Proceedings.
As a phase I multidisciplinary clinical trial, the study tests the safety, side effects and ideal dose of stem cells. Early trial findings show that patient response varies. The Mayo team plans to continue analyzing patient responses, and further results will be published on the other nine trial participants.
Read more from the study team in this Center for Regenerative Medicine blog post.
“In this case report, the first patient was a superresponder, but there are other patients in the trial who are moderate responders and nonresponders,” says Mohamad Bydon, M.D., a Mayo Clinic neurologic surgeon and first author of the report. “One of our objectives in this study and future studies is to better delineate who will be a responder and why patients respond differently to stem cell injections.
“The findings to date will be encouraging to patients with spinal cord injuries, as we are exploring an increasing array of options for treatment that might improve physical function after these devastating injuries.”
Between 250,000 and 500,000 people worldwide suffer a spinal cord injury each year, often with life-changing loss of sensory and motor function, according to the World Health Organization. Up to 90% of these cases are from traumatic causes.
All subjects enrolled in this study received fat-derived stem cell treatment, which is experimental and is not approved by the Food and Drug Administration (FDA) for large-scale use. However, the FDA allowed its use in this research.
In the case report, the patient, then 53, injured the spinal cord in his neck in a 2017 surfing accident. He suffered a complete loss of function below the level of injury, meaning he could not move or feel anything below his neck. He had surgery to decompress and fuse his cervical vertebrae. Over the next few months, with physical and occupational therapy, he regained limited ability to use his arms and legs, and some sensory function improved. However, his progress plateaued at six months after his injury.
The patient enrolled in the study nine months after his injury. His stem cells were collected by taking a small amount of fat from his abdomen. Over eight weeks, the cells were expanded in the laboratory to 100 million cells. Then the stem cells were injected into the patient’s lumbar spine, in the lower back, 11 months after his injury.
“We want to intervene when the physical function has plateaued, so that we do not allow the intervention to take credit for early improvements that occur as part of the natural history with many spinal cord injuries. In this case, the patient was injected with stem cells nearly one year after his injury,” Dr. Bydon says.
The patient was observed at baseline and at regular intervals over 18 months following injection. His physical therapy scores improved. For example, in the 10-meter walk test, the patient’s baseline of 57.72 seconds improved at 15 months to 23 seconds. And in the ambulation test, the patient’s baseline of 635 feet for 12.8 minutes improved at 15 months to 2,200 feet for 34 minutes.
The patient’s occupational therapy scores also improved, such as grip and pinch strength, and manual dexterity. His sensory scores improved, with pin prick and light touch tests, as did his mental health score.
The stem cells migrate to the highest level of inflammation, which is at the level of spinal cord injury, but the cells’ mechanism of interacting with the spinal cord is not fully understood, Dr. Bydon says. As part of the study, investigators collected cerebrospinal fluid on all of the patients to look for biological markers that might give clues to healing. Biological markers are important because they can help identify the critical processes that lead to spinal cord injury at a cellular level and could lead to new regenerative therapies.
“Regenerative medicine is an evolving field,” says Wenchun Qu, M.D., Ph.D., a Mayo Clinic physiatrist and pain specialist, and senior author of the report. “Mayo’s research and use of stem cells are informed by years of rigorous scientific investigation. We strive to ensure that patients who receive stem cells are fully educated in the risks, benefits, alternatives and unknowns about these therapies. Through our clinical trials with stem cells, we are learning from and improving these procedures.”
Further study is needed to scientifically verify the effectiveness of stem cell therapy for paralysis from spinal cord injury, the authors note. It is uncertain when or if this procedure will have FDA approval for routine clinical care.
Other researchers involved in this study were Allan Dietz, Ph.D.; Sandy Goncalves; F.M. Moinuddin, Ph.D.; Mohammed Ali Alvi, M.B.B.S.; Anshit Goyal, M.B.B.S.; Yagiz Yolcu, M.D.; Christine Hunt, D.O.; Kristin Garlanger, D.O.; Ronald Reeves, M.D.; Andre Terzic, M.D., Ph.D.; and Anthony Windebank, M.D. — all from Mayo Clinic.
The cell product was developed and manufactured in the Mayo Clinic Immune, Progenitor and Cell Therapeutics (IMPACT) Lab directed by Dr. Dietz.
This research was funded by grants from Regenerative Medicine Minnesota and Mayo Clinic Transform the Practice and supported by Mayo Clinic Center for Regenerative Medicine.
The authors have no relevant disclosures or conflicts of interest to report.
About Mayo Clinic Proceedings
Mayo Clinic Proceedings is a monthly peer-reviewed medical journal that publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research, and clinical epidemiology. Mayo Clinic Proceedings is sponsored by the Mayo Foundation for Medical Education and Research as part of its commitment to physician education. It publishes submissions from authors worldwide. The journal has been published for more than 90 years and has a circulation of 127,000. Visit the Mayo Clinic Proceedings website to view articles.
About Mayo Clinic Center for Regenerative Medicine
Mayo Clinic Center for Regenerative Medicine seeks to integrate, develop and deploy new regenerative medicine products and services that continually differentiate Mayo’s practice to draw patients from around the world for complex care. Learn more on the Center for Regenerative Medicine website.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news and An Inside Look at Mayo Clinic for more information about Mayo.